The Acceptance of Overall Survival Extrapolation Methods in Solid Tumor Treatments by Health Technology Assessment Agencies in England, France, and Australia between 2017 and 2022.

BackgroundSurvival extrapolation is used to predict patients' overall survival beyond clinical trial follow-up. It can significantly affect the results of a cost-effectiveness analysis and subsequent pricing and reimbursement decisions. However, selecting an appropriate model involves subjectivity, leading to discrepancies between methods submitted by manufacturers and those accepted by health technology assessment (HTA) agencies.

Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review.

Introduction: Health technology assessment (HTA) agencies express a clear preference for randomized controlled trials when assessing the comparative efficacy of two or more treatments. However, an indirect treatment comparison (ITC) is often necessary where a direct comparison is unavailable or, in some cases, not possible. Numerous ITC techniques are described in the literature.

Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.

Introduction: A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the comparative efficacy of brolucizumab relative to other anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) at 1 and 2 years, and overall safety and injection frequency of each treatment.

Methods: An SLR identifying randomized controlled trials (RCTs) published before June 2021 according to a pre-specified protocol was followed by a Bayesian NMA to compare brolucizumab (6 mg q12w/q8w) against sham and all relevant anti-VEGF regimens. Pooled mean injection frequency, serious adverse ocular events, and discontinuation rates were estimated for each treatment regimen.